Clinical Research Directory
Browse clinical research sites, groups, and studies.
ToFAcitinib in Early Active Axial SpondyloarThritis:
Sponsor: Charite University, Berlin, Germany
Summary
This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least one NSAID, with objective signs of inflammation.
Official title: ToFAcitinib in Early Active Axial SpondyloarThritis: a Prospective, Randomized, Double-BLind, PlAcebo-CoNtrolled MulticEntre Study
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2023-11-10
Completion Date
2026-06
Last Updated
2024-11-26
Healthy Volunteers
No
Conditions
Interventions
Tofacitinib 5 MG
Patients receive Tofacitinib and Naproxene
Locations (1)
Charité Universitätsmedizin Berlin
Berlin, Germany